Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics, Inc. updated its corporate presentation on August 6, 2026. The materials are used for presentations at healthcare conferences and in meetings with analysts, existing stockholders, and other interested parties.
The updated presentation is provided as Exhibit 99.1 and is incorporated by reference, making its contents part of the company’s public disclosures.
Iovance Biotherapeutics, Inc. reported Q2 2026 revenue of $99,313 (in thousands), compared with $59,952 a year earlier, driven by Amtagvi at $90,721 and Proleukin at $8,592 (each in thousands). First-half 2026 revenue was $170,743 versus $109,276 (in thousands).
Total Q2 costs and expenses were $151,218 (in thousands) versus $173,726, producing a loss from operations of $51,905 and a net loss of $47,315, or $0.11 per share, compared with a Q2 2025 net loss of $111,658, or $0.33 per share.
As of June 30, 2026, cash, cash equivalents, short-term investments and restricted cash totaled $303.7 million, and net cash used in operating activities for the first half was $132,915 (in thousands). The company raised $148,081 (in thousands) from common stock sales and believes existing capital will fund planned operations for at least twelve months. Amtagvi has approvals in the U.S., Canada and Australia, with additional marketing applications under review, while registrational trials continue in frontline advanced melanoma, previously treated advanced non-small cell lung cancer and select sarcomas.
Iovance Biotherapeutics reported record second-quarter 2026 revenue of $99.3 million, up 66% year over year, with roughly $91 million from Amtagvi and gross margin of 56%. Operating loss narrowed to $51.9 million and net loss to $47.3 million, while six-month net loss improved to $126.4 million from $227.8 million.
Management is reviewing its prior 2026 revenue guidance of $350–$370 million and plans to update it in the third quarter. The cash position, including cash, cash equivalents, short-term investments and restricted cash, was about $304 million as of June 30, 2026, which the company expects will fund operations into the second half of 2028.
The update also highlights progress across the TIL pipeline: Fast Track Designation for lifileucel in soft tissue sarcomas, advancing registrational programs in metastatic non-squamous NSCLC and advanced melanoma, next-generation gene-edited and IL-12 tethered TIL therapies, and expanding global Amtagvi access with recent approval in Australia and ongoing reviews in the UK and Switzerland.
BlackRock, Inc. reports a significant ownership position in IOVANCE BIOTHERAPEUTICS, INC. common stock. As of June 30, 2026, BlackRock and certain reporting business units beneficially owned 33,366,587 shares, representing 7.5% of the outstanding common stock. BlackRock has sole voting power over 32,842,318 shares and sole dispositive power over 33,366,587 shares, with no shared voting or dispositive power. The shares are held on behalf of various underlying clients, and no single underlying person is stated to have more than five percent of Iovance’s total outstanding common shares.
Iovance Biotherapeutics, Inc. updated its corporate presentation used for investor and conference meetings, outlining commercial progress, pipeline data, and financial guidance. The company highlights Amtagvi as the first FDA-approved one-time T cell therapy for solid tumors in second-line and later advanced melanoma, with more than 1,500 patients treated across commercial and clinical use.
The presentation reiterates Q2 2026 revenue guidance of $86M–$88M and full-year 2026 revenue guidance of $350M–$370M, supported by cash of about $319M as of March 31, 2026 and stated cash runway into 2028. Iovance reports over 90 authorized treatment centers, more than 200 million covered patient lives, and broad payer coverage generally aligned with clinical data and guidelines.
Clinical data summaries emphasize deep and durable responses in advanced melanoma, early but encouraging results in nonsquamous non-small cell lung cancer and soft tissue sarcomas, and proof-of-concept efforts in endometrial cancer. The company also details next-generation TIL and IL-2/IL-12-based programs intended to enhance efficacy and durability in solid tumors.
WEISER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS director Michael Weiser received a grant of 90,316 deferred restricted stock units on June 16, 2026. Each unit represents one share of common stock under the 2018 Equity Incentive Plan. The units vest on the earlier of one year after the grant date or just before the next annual shareholder meeting, and delivery of shares is deferred until specific future events. Following this grant, Weiser holds 90,316 deferred restricted stock units directly.
IOVANCE BIOTHERAPEUTICS director Iain D. Dukes received a grant of 180,632 deferred restricted stock units (DRSUs) linked to the company’s common stock. The award was made at no cash exercise price under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if Dukes continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Actual common shares are issued later, upon specified events such as board departure, a qualifying change in control, or ten years after the grant date.
Countouriotis Athena reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Athena Countouriotis received a grant of 90,316 deferred restricted stock units (DRSUs) linked to common stock, awarded at no cash cost under the company’s 2018 Equity Incentive Plan.
The DRSUs vest if she continues providing service and will vest on the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, delivery of common shares is deferred until specific events such as board service ending, a qualifying change in control, or ten years after the grant date.
Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.
The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 15,000 restricted stock units, each representing one share of common stock. All 15,000 RSUs were reported as directly owned after the award. The grant vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining units vesting in eight equal quarterly installments over the following two years, contingent on continued employment.